Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Panel Narrowly Rejects Qnexa

July 16, 2010 6:57 am | by Matthew Perrone | News | Comments

A panel of federal health experts dealt a surprising setback to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.


MIP Columns

July 15, 2010 8:26 am | Product Releases | Comments

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of high-performance, AFFINILUTE MIP (Molecularly Imprinted Polymers) columns for analytical sample preparation.


Quick Adjust Platform

July 15, 2010 8:18 am | Product Releases | Comments

Prior Scientific has just introduced the ZDeck Quick Adjust Platform System for Olympus BX51WI and BX61WI microscopes. The ZDeck Quick Adjust Platform System increases productivity by allowing the user to image multiple areas of interest with unsurpassed speed and precision.


Arthritis Drug Can Also Treat Vasculitis

July 15, 2010 8:10 am | News | Comments

Researchers have reported that Rituximab, a drug that is FDA approved to treat B cell lymphoma and rheumatoid arthritis, can also treat severe vasculitis as well as the current standard therapy.


Alzheimer's Gene Changes Brain Protein Shape

July 15, 2010 8:04 am | News | Comments

Researchers have used a newly discovered class of biomarkers to investigate the possibility that the shape of brain protein deposits is different in people with Alzheimer's who have the highest-risk gene type than in those with the neutral risk gene.


Merck Wraps Up Purchase of Millipore

July 15, 2010 7:59 am | News | Comments

Merck KGaA, a global pharmaceutical and chemical company, announced the successful completion of its acquisition of Millipore Corporation for $7 billion.


Novartis Profits Up 19% In Q2

July 15, 2010 7:50 am | News | Comments

Drug maker Novartis AG reported a second-quarter increase in net profit of 19%, as sales in its pharmaceuticals business offset health care cost-cutting efforts by some European governments.


Perifosine Granted Second Orphan Drug Status

July 15, 2010 7:46 am | News | Comments

Keryx Biopharmaceuticals Inc. said that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children.


Lorcaserin Deemed Safe And Effective

July 15, 2010 7:40 am | by Mike Stobbe | News | Comments

An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.


Novartis Shelling Out $152M In Settlements

July 15, 2010 7:36 am | by Larry Neumeister | News | Comments

Novartis will pay up to $152.5 million to potentially thousands of women after a jury found it discriminated against them by paying them less than men, the pharmaceutical company and plaintiffs' lawyers announced Wednesday after a deal was struck.


FDA Panels Votes to Keep Avandia

July 15, 2010 7:33 am | by Matthew Perrone | News | Comments

GlaxoSmithKline's drug Avandia should stay on the market, federal health experts voted, but the controversial diabetes pill should be subject to new restrictions due to risky heart side effects.


Protease Assay

July 15, 2010 7:16 am | Product Releases | Comments

FLEXYTE protease assays harness the power and potential of fluorescence lifetime technology for robust, efficient and economical screening of proteases.


Fluorescing DNA Dye

July 15, 2010 7:11 am | Product Releases | Comments

DRAQ7 from Biostatus Ltd. is a live cell-impermeant far-red fluorescing DNA dye with the same spectral properties that already made DRAQ5 a reagent of choice.


Screening Method for Extra Large Libraries Developed

July 15, 2010 7:03 am | News | Comments

The search for new drug compounds is probably worse than looking for a needle in a haystack because scientists are limited in the size of the haystacks they can rummage through—time and money make it virtually impossible to screen or search through super-large libraries of potential compounds.


Elemental Analyser

July 15, 2010 6:56 am | Product Releases | Comments

With its wide linear range, combined static and dynamic combustion technology and horizontal furnace design allowing for removal of residues between runs, the Exeter Analytical CE-440 CHN/O/S elemental analyzer is uniquely capable of accurately analyzing the widest range of sample types - quickly, easily and reliably.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.